0H19 Stock Chart & Stats
kr14.24
kr0.00(0.00%)
At close: 4:00 PM EDT
kr14.24
kr0.00(0.00%)
Day’s Range― - ―
52-Week Rangekr14.24 - kr38.25
Previous CloseN/A
Volume0.00
Average Volume (3M)26.00
Market Cap
kr470.05M
Enterprise Valuekr576.03
Total Cash (Recent Filing)kr276.90M
Total Debt (Recent Filing)kr9.90M
Price to Earnings (P/E)―
Beta-0.40
Next Earnings
Oct 22, 2026EPS Estimate
-2.1Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-8.81
Shares Outstanding35,127,056
10 Day Avg. Volume0
30 Day Avg. Volume26
Financial Highlights & Ratios
PEG Ratio0.22
Price to Book (P/B)2.12
Price to Sales (P/S)40.09
P/FCF Ratio6.02
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)-9.78
Revenue Forecast (FY)kr19.00M
Bulls Say, Bears Say
Bulls Say
Improved SolvencyThe sharp improvement in debt relative to equity strengthens Orexo’s solvency and provides more flexibility than in earlier highly leveraged periods. Although profitability remains weak, a less burdensome capital structure can support development funding and improve resilience through the next several quarters.
Pipeline Progress And Long IP RunwaysMultiple development programs are advancing, while long IP protection for key assets could support extended commercial opportunity if clinical and regulatory milestones are achieved. This combination gives Orexo several potential growth avenues beyond its pressured current revenue base.
External Funding And Partnership PotentialBARDA support reduces the amount of Orexo’s own capital required for OX390 development and validates a pathway for non-dilutive funding. Intensifying partnering efforts for OX640 and Izipry could further share development costs and broaden future commercialization capacity.
Bears Say
Deep Losses And Revenue ContractionOrexo’s current operating model is not covering its cost base: profitability is deeply negative and revenue has contracted materially. Persistent losses reduce internal funding capacity and make future earnings dependent on successful product launches, pipeline execution, or external financing.
Severe Cash Burn And VolatilityThe sharp quarterly cash outflow can rapidly reduce the resources available for clinical development, regulatory work, and ordinary operations. While other periods showed positive TTM cash flow, the continuing net loss and volatile cash profile make that improvement difficult to regard as durable.
DOJ Investigation And Financing UncertaintyAn unresolved DOJ matter creates an uncertain future cash obligation and continues to generate legal expense. It can also constrain financing flexibility, because management indicates greater clarity is needed before raising equity on more attractive terms, potentially slowing investment in growth programs.
Orexo AB News
0H19 FAQ
What was Orexo AB’s price range in the past 12 months?
Orexo AB lowest share price was kr14.24 and its highest was kr38.25 in the past 12 months.
What is Orexo AB’s market cap?
Orexo AB’s market cap is kr470.05M.
When is Orexo AB’s upcoming earnings report date?
Orexo AB’s upcoming earnings report date is Oct 22, 2026 which is in 21 days.
How were Orexo AB’s earnings last quarter?
Orexo AB released its earnings results on Jul 16, 2026. The company reported -kr2.2 earnings per share for the quarter, missing the consensus estimate of -kr1.6 by -kr0.6.
Is Orexo AB overvalued?
According to Wall Street analysts Orexo AB’s price is currently Overvalued.
Does Orexo AB pay dividends?
Orexo AB does not currently pay dividends.
What is Orexo AB’s EPS estimate?
Orexo AB’s EPS estimate is -2.1.
How many shares outstanding does Orexo AB have?
Orexo AB has 35,127,056 shares outstanding.
What happened to Orexo AB’s price movement after its last earnings report?
Orexo AB reported an EPS of -kr2.2 in its last earnings report, missing expectations of -kr1.6. Following the earnings report the stock price went same 0%.
Which hedge fund is a major shareholder of Orexo AB?
Currently, no hedge funds are holding shares in GB:0H19
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Orexo AB
Orexo AB (publ), a specialty pharmaceutical company, develops and commercializes pharmaceuticals and digital therapies in the United States, European Union, the United Kingdom, and internationally. Its products include Zubsolv tablets for the treatment of opioid use disorder; Abstral for the treatment of breakthrough pain in cancer patients; and Edluar for the treatment of insomnia. The company is developing OX124 for opioid overdose; OX125 for rescue medication and opioid overdose; OX640 to treat anaphylaxis with powder-based epinephrine; and OX-MPI for the treatment of endometriosis. Its digital therapies include deprexis for the treatment of depression; vorvida for alcohol management; and modia for opioid use disorder. The company has a collaboration agreement with Abera Bioscience AB to develop nasal powder vaccines based on the AmorphOX technology. Orexo AB (publ) was founded in 1994 and is headquartered in Uppsala, Sweden.
0H19 Company Deck
0H19 Earnings Call
Q2 2026
0:00 / 0:00
Earnings Call Sentiment|Neutral
The call presents a mixed picture: strong scientific and programmatic progress (positive in vivo data for OX390, Izipry filing on track, OX640 progression, BARDA funding, and business development momentum) and valuable strategic assets (long IP life, AmorphOX platform interest). However, short-term financials are challenged by material one-off costs (GAIA settlement), ongoing DOJ uncertainty, substantial quarterly cash burn and low revenues. Management has clear plans to reduce run-rate OpEx and pursue partnerships and financing, but timing and DOJ resolution are key near-term risks.View all GB:0H19 earnings summariesTechnical Analysis
Swedish Orphan Biovitrum AB
―
Camurus AB
―
AlzeCure Pharma AB
―
IRLAB Therapeutics AB Class A
―
Xspray Pharma AB
―